Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Change in Account Payables (2019 - 2025)

Black Diamond Therapeutics' Change in Account Payables history spans 5 years, with the latest figure at -$396000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 119.45% year-over-year to -$396000.0; the TTM value through Dec 2025 reached -$3.4 million, down 303.68%, while the annual FY2025 figure was -$3.4 million, 303.68% down from the prior year.
  • Change in Account Payables reached -$396000.0 in Q4 2025 per BDTX's latest filing, down from $204000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.0 million in Q4 2024 to a low of -$1.9 million in Q2 2025.
  • Average Change in Account Payables over 3 years is $27333.3, with a median of -$396000.0 recorded in 2025.
  • Peak YoY movement for Change in Account Payables: dropped 16.83% in 2021, then plummeted 328.87% in 2025.
  • A 3-year view of Change in Account Payables shows it stood at $2.0 million in 2021, then increased by 2.26% to $2.0 million in 2024, then crashed by 119.45% to -$396000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Change in Account Payables are -$396000.0 (Q4 2025), $204000.0 (Q3 2025), and -$1.9 million (Q2 2025).